
|Videos|September 21, 2022
Dr. Ornstein on antibody-drug conjugates for immunotherapy-refractory urothelial carcinoma
Author(s)Urology Times staff
“The management of patients with advanced urothelial carcinoma whose cancer has progressed on immunotherapy presents a unique challenge,” says Moshe Ornstein, MD.
Advertisement
Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the emergence of antibody-drug conjugates as a treatment option for patients with immune checkpoint inhibitor–refractory advanced urothelial carcinoma.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
Modern frameworks for treating high-risk non–muscle invasive bladder cancer
5


















